Switch Therapeutics, a South San Francisco, CA-based, preclinical stage biotechnology firm, raised $52M in Sequence A funding.
The spherical was led by Perception Companions and UCB Ventures, with participation from current buyers, together with Upfront Ventures, BOLD Capital Companions, Eli Lilly and Firm, Ono Enterprise Funding, Digitalis Ventures, Dolby Household Ventures, Free Movement Ventures, PhiFund Ventures.
Led by CEO Dee Datta, and CTO Si-ping Han, Ph.D., Change Therapeutics is an rising biotechnology firm that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the aim of treating a spread of illnesses – affecting the central nervous system and systemic indications – with important unmet want. The CASi (Conditionally Activated siRNA) platform – primarily based on know-how developed by famend researchers within the subject of RNA and drug growth from Caltech, Harvard Medical Faculty and Metropolis of Hope – combines advantageous properties of each single and double-stranded RNAs in a single molecule, permitting for cell selective RNAi exercise. CASi molecules use a small interfering RNA (siRNA) construction with structural extensions to permit for docking to a sensor developed by Change. The sensor permits environment friendly supply of the siRNA whereas regulating the siRNA’s exercise to “change on” solely in chosen cells.
The corporate intends to make use of the funds to pick out and advance a growth candidate for its lead program for the remedy of a central nervous system illness, discover alternatives to increase its CASi platform into new areas by way of potential pharmaceutical collaborations, and recruit high R&D and company expertise to assist speed up its progress
FinSMEs
14/03/2023
